GD
CytoMed Therapeutics Limited
GDTC · NASDAQ
$0.86 +6.87% (+$0.06)
1M -5.70%
Market Cap $13.0M
P/E Ratio -
Div. Yield -
ROE 70.74%
Piotroski F-Score Weak
2/9Valuation
44 /100
Fair P/S 20.28x
P/B 1.99x
P/E N/A
Growth
22 /100
Declining Rev. growth 4.42%
Book val. growth 123.05%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 20.48%
Net margin 754.67%
FCF margin 986.02%
Quality
1 /100
Poor ROIC 58.88%
ROE 70.74%
Asset turnover 0.08x
Debt
69 /100
Low Debt/Equity 0.07x
Current ratio 5.17x
Int. coverage -276.39x
Stability
13 /100
Unstable Beta 0.05x
Rev. volatility 229.77%
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o GDTC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Chee Kong Choo
Employees
42
Headquarters
Singapore
Nadchodzące wydarzenia
13 LIS
Earnings
Upcoming earnings report